Chronic Disease
Chronic Disease: A disease that persists for an extended amount of time. In order for the disease to be considered chronic, it lasts for about 3 months or more. These diseases often cannot be prevented by vaccines or cured by medication, nor do they just disappear.
What's Popular in Chronic Disease
DEC 14, 2021
6:00 AM PST
C.E. CREDITS
DEC 14, 2021
6:00 AM PST
Date: December 14, 2021 Time: 6:00am (PST), 9:00am (EST) Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus and is a leading cause of acute viral hepatitis worldwide. The...
NOV 30, 2021
11:00 AM PST
C.E. CREDITS
NOV 30, 2021
11:00 AM PST
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
OCT 13, 2021
10:30 AM PDT
C.E. CREDITS
OCT 13, 2021
10:30 AM PDT
Severe SARS-CoV-2 infection often leads to development of acute respiratory distress syndrome (ARDS), with profound pulmonary patho-histological changes post-mortem. In this study, we utiliz...
AUG 24, 2021
8:00 AM PDT
C.E. CREDITS
AUG 24, 2021
8:00 AM PDT
Date: August 24, 2021 Time: 8:00am (PST), 11:00am (EST) Liver cancer is the third cause of cancer-related mortality worldwide. Most patients have chronic liver disease, which has allowed...
APR 21, 2021
5:00 PM CEST
APR 21, 2021
5:00 PM CEST
Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
C.E. CREDITS
In mammals, DNA methylation is an epigenetic mark that regulates gene expression by serving as a maintainable mark whose absence marks promoters and enhancers. Recent epidemiological studies...
APR 19, 2021
11:15 AM EDT
C.E. CREDITS
APR 19, 2021
11:15 AM EDT
ASH Anticoagulation Guidelines in Patients with COVID-19: A moving target The American Society of Hematology (ASH) published in February 2021 “Anticoagulation Guidelines in Patients wi...
